Novel regulations of the angiotensin II receptor type 1 by calmodulin

被引:6
|
作者
Ehlers, Kevin [1 ]
Clements, Robert [1 ]
VerMeer, Mark [1 ]
Giles, Jennifer [1 ]
Tran, Quang-Kim [1 ]
机构
[1] Des Moines Univ, Osteopath Med Ctr, Dept Physiol & Pharmacol, 3200 Grand Ave,Ryan Hall 258, Des Moines, IA 50312 USA
基金
美国国家卫生研究院;
关键词
Angiotensin II receptor type 1; Calmodulin; Calcium; FRET biosensor; Angiotensin II; SMOOTH-MUSCLE-CELLS; PLASMA-MEMBRANE; BINDING; PROTEINS; NETWORK; PHOSPHORYLATION; INTERACTS; DOMAINS; SYSTEM; KINASE;
D O I
10.1016/j.bcp.2018.03.027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The angiotensin II receptor type 1 (AT(1)R) mediates many Ca2+-dependent actions of angiotensin II (AngII). Calmodulin (CaM) is a key transducer of Ca2+ signals in cells. Two locations on the receptor's submembrane domains (SMD) 3 and 4 are known to interact with CaM. However, the binding sites for CaM, biochemical properties of the interactions, and their functional impact are not fully understood. Using a FRET-based screening method, we identified a new binding site for CaM on SMD2 (a.a. 125-141), in addition to SMD3 and the juxtamembranous region of SMD4 (SMD4(JM), a.a., 309-327). Simultaneous measurements of CaM binding and free Ca2+ show that the interactions are Ca2+-dependent, with disparate K-d and EC50(Ca2+) values within the physiological range of cytoplasmic Ca2+. Full interaction between CaM and SMD3 requires the entire domain (a.a. 215-242) and has an EC50(Ca2+) value in the range of resting cytoplasmic Ca2+, suggesting AT(1)R-CaM interaction can occur in resting conditions in cells. AngII induces robust ERK1/2 phosphorylation in primary vascular smooth muscle cells. This effect is suppressed by AT(1)R inhibitor losartan and virtually abolished by CaM antagonist W-7. AngII-induced ERK1/2 phosphorylation is suppressed in cells expressing mutant AT(1)R with reduced CaM binding at each identified binding domain. AngII triggers transient Ca2+ signals in cells expressing wild-type AT(1)R. These signals are reduced in cells expressing mutant AT(1)R with reduced CaM binding at SMD3 or SMD4(JM), but are very slow-rising, low amplitude signal in cells expressing AT(1)R. with reduced CaM binding at SMD2. The data indicate that CaM interactions with AT(1)R can occur at various domains, with different affinities, at different physiological Ca2+ levels, and are important for AT(1)R-mediated signaling.
引用
收藏
页码:187 / 200
页数:14
相关论文
共 50 条
  • [31] Understanding Angiotensin II Type 1 Receptor Signaling in Vascular Pathophysiology
    Eguchi, Satoru
    Kawai, Tatsuo
    Scalia, Rosario
    Rizzo, Victor
    HYPERTENSION, 2018, 71 (05) : 804 - 810
  • [32] Possible Role of Angiotensin-Converting Enzyme 2 and Activation of Angiotensin II Type 2 Receptor by Angiotensin-(1-7) in Improvement of Vascular Remodeling by Angiotensin II Type 1 Receptor Blockade
    Ohshima, Kousei
    Mogi, Masaki
    Nakaoka, Hirotomo
    Iwanami, Jun
    Min, Li-Juan
    Kanno, Harumi
    Tsukuda, Kana
    Chisaka, Toshiyuki
    Bai, Hui-Yu
    Wang, Xiao-Li
    Ogimoto, Akiyoshi
    Higaki, Jitsuo
    Horiuchi, Masatsugu
    HYPERTENSION, 2014, 63 (03) : E53 - E59
  • [33] Angiotensin II Regulates Th1 T Cell Differentiation Through Angiotensin II Type 1 Receptor-PKA-Mediated Activation of Proteasome
    Qin, Xian-Yun
    Zhang, Yun-Long
    Chi, Ya-Fei
    Yan, Bo
    Zeng, Xiang-Jun
    Li, Hui-Hua
    Liu, Ying
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 45 (04) : 1366 - 1376
  • [34] Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone
    Fukuyama, K
    Ichiki, T
    Takeda, K
    Tokunou, T
    Iino, N
    Masuda, S
    Ishibashi, M
    Egashira, K
    Shimokawa, H
    Hirano, K
    Kanaide, H
    Takeshita, A
    HYPERTENSION, 2003, 41 (03) : 598 - 603
  • [35] Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase
    Eguchi, S
    Inagami, T
    REGULATORY PEPTIDES, 2000, 91 (1-3) : 13 - 20
  • [36] AGONIST-INDUCED PHOSPHORYLATION OF THE VASCULAR TYPE-1 ANGIOTENSIN-II RECEPTOR
    KAI, H
    GRIENDLING, KK
    LASSEGUE, B
    OLLERENSHAW, JD
    RUNGE, MS
    ALEXANDER, RW
    HYPERTENSION, 1994, 24 (04) : 523 - 527
  • [37] Effectiveness and Safety of a Therapeutic Vaccine Against Angiotensin II Receptor Type 1 in Hypertensive Animals
    Chen, Xiao
    Qiu, Zhihua
    Yang, Shijun
    Ding, Dan
    Chen, Fen
    Zhou, Yanzhao
    Wang, Min
    Lin, Jibin
    Yu, Xian
    Zhou, Zihua
    Liao, Yuhua
    HYPERTENSION, 2013, 61 (02) : 408 - +
  • [38] NF-κB and CREB Are Required for Angiotensin II Type 1 Receptor Upregulation in Neurons
    Haack, Karla K. V.
    Mitra, Amit K.
    Zucker, Irving H.
    PLOS ONE, 2013, 8 (11):
  • [39] Angiotensin II type 1 receptor signalling regulates microRNA differentially in cardiac fibroblasts and myocytes
    Jeppesen, Pia Lindgren
    Christensen, Gitte Lund
    Schneider, Mikael
    Nossent, Anne Yael
    Jensen, Hasse Bronnum
    Andersen, Ditte Caroline
    Eskildsen, Tilde
    Gammeltoft, Steen
    Hansen, Jakob Lerche
    Sheikh, Soren Paludan
    BRITISH JOURNAL OF PHARMACOLOGY, 2011, 164 (02) : 394 - 404
  • [40] The mechanisms behind decreased internalization of angiotensin II type 1 receptor
    Bian, Jingwei
    Zhang, Suli
    Yi, Ming
    Yue, Mingming
    Liu, Huirong
    VASCULAR PHARMACOLOGY, 2018, 103 : 1 - 7